PLXND1 and systemic sclerosis: On the contrary, when H-MVECs were co-incubated with sera from patients with SSc and Sema3E-binding PlxnD1 soluble peptide, their angiogenic capacity was significantly increased compared with cells treated with sera from patients with SSc alone (p <0.05) (Fig. 6).